Status epilepticus (SE) is a medical emergency with high mortality rate. Common causes of SE include noncompliance with antiepileptic medications, drug- and alcohol-related etiologies, and central nervous system (CNS) infections. Because prolonged seizures can cause neuronal damage, treatment should be initiated promptly to avoid potential complications. Previous studies support intravenous (IV) lorazepam as first-line therapy and IV phenytoin or fosphenytoin as a second-line medication. If first-and second-line medications fail to control SE, further treatment with propofol, pentobarbital, midazolam, or other medications should be considered. Many of the drugs currently used to control SE are associated with sedation, respiratory suppression, hypotension, cardiac dysrhythmia, and anaphylactic reactions. Therefore, IV valproate or other newer antiepileptic drugs may be considered as an alternative third-line therapy for those who cannot tolerate the hypotensive effects of other anticonvulsants. This paper reviews comparative effectiveness and safety concerns among frequently used medications for SE.
DeLorenzo RJ , Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology . 1996;46:1029-1035.
2.
Hesdorffer DC , Logroscino G., Cascino G., Annegers JF, Hauser WAIncidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology.1998;50:735-741.
Theodore WH, Porter RJ, Albert P., et al. The secondarily generalized tonic-clonic seizure: a videotape analysis. Neurology. 1994;44:1403-1407.
5.
Rossetti AO, Hurwitz S., Logroscino G., Bromfield EBPrognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry . 2006;77:611-615.
6.
Epilepsy Foundation of America's Working Group on Status Epilepticus. Treatment of convulsive status epilepticus.Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA.1993;270: 854-859.
7.
Lothman E.The biochemical basis and pathophysiology of status epilepticus. Neurology. 1990;40:13-23.
8.
Nevander G., Ingvar M., Auer R., Siesjo BKStatus epilepticus in well-oxygenated rats causes neuronal necrosis. Ann Neurol.1985;18:281-290.
9.
Alldredge BK , Lowenstein DHStatus epilepticus: new concepts. Curr Opin Neurol.1999;12:183-190.
10.
Lowenstein DH, Bleck T., Macdonald RLIt's time to revise the definition of status epilepticus. Epilepsia. 1999;40:120-122.
11.
DeLorenzo RJStatus epilepticus: concepts in diagnosis and treatment. Semin Neurol.1990;10:396-405.
12.
Treiman DMElectroclinical features of status epilepticus. J Clin Neurophysiol.1995;12:343-362.
13.
Treiman DM, Walton NY, Kendrick C.A progressive sequence of electroencephalographic changes during generalized convulsive status epilepticus. Epilepsy Res.1990;5:49-60.
Bleck TPAdvances in the management of refractory status epilepticus. Crit Care Med.1993;21:955-957.
16.
Jagoda A., Riggio S.Refractory status epilepticus in adults. Ann Emerg Med.1993;22:1337-1348.
17.
Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med.1998; 339:792-798.
18.
Alldredge BK , Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med.2001;345: 631-637.
19.
Lowenstein DH, Alldredge BK, Allen F., et al. The prehospital treatment of status epilepticus (PHTSE) study: design and methodology. Control Clin Trials. 2001;22:290-309.
20.
Bleck TPManagement approaches to prolonged seizures and status epilepticus. Epilepsia. 1999;40(suppl 1):S59-S63.
21.
Treiman DMGeneral principles of treatment: responsive and intractable status epilepticus in adults. Adv Neurol.1983;34:377-384.
22.
Treiman DMTherapy of status epilepticus in adults and children. Curr Opin Neurol.2001;14:203-210.
23.
Lowenstein DH, Alldredge BKStatus epilepticus at an urban public hospital in the 1980s. Neurology. 1993;43:483-488.
24.
DeLorenzo RJ , Waterhouse EJ, Towne AR, et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia . 1998;39:833-840.
25.
Cock HR, Schapira AHA comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus. QJM.2002;95:225-231.
26.
Treiman DMPharmacokinetics and clinical use of benzodiazepines in the management of status epilepticus. Epilepsia. 1989;30(suppl 2):S4-S10.
27.
Cook M.Treatment of epilepsy. Aust Fam Physician.1995;24:1261-1269.
28.
Bleck TPRefractory status epilepticus in 2001. Arch Neurol.2002;59:188-189.
29.
O'Brien TJ, Cascino GD, So EL, Hanna DRIncidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology.1998;51: 1034-1039.
30.
Ramsay RE, DeToledo J.Intravenous administration of fosphenytoin: options for the management of seizures. Neurology. 1996;46:S17-S19.
31.
DeToledo JC, Ramsay REFosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. Drug Saf.2000;22:459-466.
32.
Graves N.Pharmacoeconomic considerations in treatment options for acute seizures. J Child Neurol.1998;13(suppl 1): S27-S29.
33.
Ramsay RE, Wilder BJ, Uthman BM, et al. Intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin. Epilepsy Res.1997 ;28:181-187.
34.
Devinsky O. , Leppik I., Willmore LJ, et al. Safety of intravenous valproate. Ann Neurol.1995;38:670-674.
35.
Hodges BM, Mazur JEIntravenous valproate in status epilepticus. Ann Pharmacother.2001;35:1465-1470.
36.
Hovinga CA, Chicella MF, Rose DF, Eades SK, Dalton JT, Phelps SJUse of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. Ann Pharmacother.1999;33:579-584.
37.
Kaplan PWIntravenous valproate treatment of generalized nonconvulsive status epilepticus . Clin Electroencephalogr. 1999;30:1-4.
38.
Sheth RD, Gidal BEIntravenous valproic acid for myoclonic status epilepticus. Neurology. 2000;54:1201.
39.
Giroud M., Dumas R.Treatment of status epilepticus by sodium valproate. Neurophysiol Clin.1988;18:21-32.
40.
Sinha S., Naritoku DKIntravenous valproate is well tolerated in unstable patients with status epilepticus . Neurology. 2000;55:722-724.
41.
Wheless JW, Vazquez BR, Kanner AM, Ramsay RE, Morton L., Pellock JMRapid infusion with valproate sodium is well tolerated in patients with epilepsy . Neurology. 2004;63:1507-1508.
42.
Uberall MA, Trollmann R., Wunsiedler U., Wenzel D.Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology. 2000;54:2188-2189.
43.
Venkataraman V., Wheless JWSafety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res.1999;35:147-153.
44.
Yu KT, Mills S., Thompson N., Cunanan C.Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia.2003;44:724-726.
45.
Kumar A., Bleck TPIntravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med.1992;20: 483-438.
46.
Prasad A., Worrall BB, Bertram EH, Bleck TPPropofol and midazolam in the treatment of refractory status epilepticus. Epilepsia. 2001;42:380-386.
47.
Claassen J. , Hirsch LJ, Emerson RG, Bates JE, Thompson TB, Mayer SAContinuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology . 2001;57:1036-1042.
48.
Mayhue FEIM midazolam for status epilepticus in the emergency department. Ann Emerg Med.1988;17:643-645.
49.
Wolfe TR, Macfarlane TCIntranasal midazolam therapy for pediatric status epilepticus. Am J Emerg Med.2006;24: 343-346.
50.
LeDuc TJ, Goellner WE, el Sanadi N.Out-of-hospital midazolam for status epilepticus. Ann Emerg Med.1996;28:377.
51.
Holmes GL, Riviello JJ Jr.Midazolam and pentobarbital for refractory status epilepticus. Pediatr Neurol.1999;20:259-264.
52.
Rashkin MC, Youngs C., Penovich P.Pentobarbital treatment of refractory status epilepticus. Neurology. 1987;37:500-503.
53.
Lowenstein DH, Alldredge BKStatus epilepticus. N Engl J Med.1998;338:970-976.
54.
Goldberg MA , McIntyre HBBarbiturates in the treatment of status epilepticus . Adv Neurol.1983;34:499-503.
55.
Vining EPUse of barbiturates and benzodiazepines in treatment of epilepsy. Neurol Clin.1986;4:617-632.
56.
Osorio I., Reed RCTreatment of refractory generalized tonicclonic status epilepticus with pentobarbital anesthesia after high-dose phenytoin. Epilepsia.1989;30:464-471.
57.
Yaffe K., Lowenstein DHPrognostic factors of pentobarbital therapy for refractory generalized status epilepticus. Neurology. 1993;43:895-900.
58.
Van Ness PCPentobarbital and EEG burst suppression in treatment of status epilepticus refractory to benzodiazepines and phenytoin. Epilepsia.1990;31:61-67.
59.
Lowenstein DH, Aminoff MJ, Simon RPBarbiturate anesthesia in the treatment of status epilepticus: clinical experience with 14 patients. Neurology. 1988;38:395-400.
60.
Krishnamurthy KB, Drislane FWDepth of EEG suppression and outcome in barbiturate anesthetic treatment for refractory status epilepticus. Epilepsia . 1999;40:759-762.
61.
O'Brien MDManagement of major status epilepticus in adults. BMJ.1990;301:918.
62.
Parviainen I., Uusaro A., Kalviainen R., Kaukanen E., Mervaala E., Ruokonen E.High-dose thiopental in the treatment of refractory status epilepticus in intensive care unit. Neurology. 2002;59:1249-1251.
63.
Lohr A. Jr, Werneck LCComparative non-randomized study with midazolam versus thiopental in children with refractory status epilepticus. Arq Neuropsiquiatr.2000;58:282-287.
64.
Ghosh IR, Langford RM, Nieminen K., Kari A., Takala J.Repetitive synchronized cyclical oscillations of multisystem parameters subsequent to high-dose thiopental therapy for status epilepticus secondary to herpes encephalitis. Br J Anaesth.2000;85:471-473.
65.
Nadal P., Nicolas JM, Font C., Vilella A., Nogue S.Pneumonia in ventilated head trauma patients: the role of thiopental therapy . Eur J Emerg Med.1995;2:14-16.
66.
Begemann M. , Rowan AJ, Tuhrim S.Treatment of refractory complex-partial status epilepticus with propofol: case report. Epilepsia.2000;41:105-109.
67.
Campostrini R., Bati MB, Giorgi C., et al. Propofol in the treatment of convulsive status epilepticus: a report of four cases. Riv Neurol.1991;61: 176-179.
68.
Harrison AM , Lugo RA, Schunk JETreatment of convulsive status epilepticus with propofol: case report. Pediatr Emerg Care.1997;13:420-422.
69.
Rossetti AO , Reichhart MD, Schaller MD, Despland PA, Bogousslavsky J.Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia. 2004;45:757-763.
70.
Stecker MM, Kramer TH, Raps EC, O'Meeghan R., Dulaney E., Skaar DJTreatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia.1998;39:18-26.
71.
Brown LA, Levin GMRole of propofol in refractory status epilepticus. Ann Pharmacother.1998;32:1053-1059.
72.
Finley GA, MacManus B., Sampson SE, Fernandez CV, Retallick R.Delayed seizures following sedation with propofol. Can J Anaesth.1993;40:863-865.
73.
Bray RJPropofol-infusion syndrome in children. Lancet. 1999;353:2074-2075.
74.
Claassen J., Hirsch LJ, Emerson RG, Mayer SATreatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia.2002;43: 146-153.
75.
Parke TJ, Stevens JE, Rice AS, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ.1992;305:613-616.
76.
Perry MS, Holt PJ, Sladky JTTopiramate loading for refractory status epilepticus in children. Epilepsia. 2006;47:1070-1071.
77.
Blumkin L., Lerman-Sagie T., Houri T., et al. Pediatric refractory partial status epilepticus responsive to topiramate. J Child Neurol.2005;20:239-241.
78.
Tarulli A., Drislane FWThe use of topiramate in refractory status epilepticus. Neurology . 2004;62:837.
79.
Bensalem MK , Fakhoury TATopiramate and status epilepticus: report of three cases. Epilepsy Behav.2003;4:757-760.
80.
Kahriman M. , Minecan D., Kutluay E., Selwa L., Beydoun A.Efficacy of topiramate in children with refractory status epilepticus. Epilepsia. 2003;44:1353-1356.
81.
Rupprecht S. , Franke K., Fitzek S., Witte OW, Hagemann G.Levetiracetam as a treatment option in non-convulsive status epilepticus. Epilepsy Res.2007;73:238-244.
82.
Rossetti AO , Bromfield EBDeterminants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav.2006;8:651-654.
83.
Patel NC, Landan IR, Levin J., Szaflarski J., Wilner ANThe use of levetiracetam in refractory status epilepticus. Seizure. 2006;15:137-141.
84.
Rossetti AO , Bromfield EBLevetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes. Eur Neurol.2005;54:34-38.
85.
Fujikawa DGNeuroprotective effect of ketamine administered after status epilepticus onset. Epilepsia. 1995;36:186-195.
86.
Sheth RD, Gidal BERefractory status epilepticus: response to ketamine. Neurology . 1998;51:1765-1766.
George B., Kulkarni SK, Mathur R.Motor and electrographic response of refractory experimental status epilepticus in rats and effect of calcium channel blockers. Indian J Exp Biol.2000;38:105-112.
89.
Iannetti P. , Spalice A., Parisi P.Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia . 2005;46:967-969.
90.
Rossetti AO , Logroscino G., Bromfield EBRefractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol.2005;62:1698-1702.
91.
Manno EMNew management strategies in the treatment of status epilepticus. Mayo Clin Proc.2003;78:508-518.
